User login
Recorded at the 2014 meeting of the North American Menopause Society
Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville. Dr. Kaunitz serves on the OBG Management Board of Editors.
Dr. Kaunitz reports that he receives grant or research support from Agile, Bayer, Noven, Teva, and TherapeuticsMD and is a consultant to Actavis, Bayer, Merck and Teva.
Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville. Dr. Kaunitz serves on the OBG Management Board of Editors.
Dr. Kaunitz reports that he receives grant or research support from Agile, Bayer, Noven, Teva, and TherapeuticsMD and is a consultant to Actavis, Bayer, Merck and Teva.
Andrew M. Kaunitz, MD
Professor and Associate Chairman, Department of Obstetrics and Gynecology, University of Florida College of Medicine–Jacksonville. Dr. Kaunitz serves on the OBG Management Board of Editors.
Dr. Kaunitz reports that he receives grant or research support from Agile, Bayer, Noven, Teva, and TherapeuticsMD and is a consultant to Actavis, Bayer, Merck and Teva.
Recorded at the 2014 meeting of the North American Menopause Society
Recorded at the 2014 meeting of the North American Menopause Society
